iSpecimen Inc. Corporate Update – October 2026
Trading Performance (21 Oct 2026)
| Metric | Value |
|---|---|
| Closing price (01:10 PM C.E.) | USD 0.96 |
| 24‑hour price change | +5.49 % |
| 24‑hour trading volume | USD 224.1 k |
| Shares outstanding | 2.5 million |
| Market capitalization | USD 2.3 million |
| 52‑week high | USD 36.32 (24 Oct 2025) |
| 52‑week low | USD 0.89 (20 Oct 2026) |
| Simple moving average (200 days) | USD 5.33 |
| Month‑end change | ‑27.27 % (down from the prior month) |
Proxy Statement Amendment
- Filing date: 19 Oct 2026
- Document: Definitive proxy statement amendment
- Purpose: Clarify voting requirements for the proposed reverse stock split
- Change in voting threshold: From a majority of shares to a simple majority of votes cast “FOR” over those “AGAINST.” This aligns with Delaware law and Nasdaq listing rules.
- Board recommendation: “FOR” the reverse split
- Shareholder instruction options: Submit or modify instructions via the company’s website, telephone, or virtual meeting until the adjourned meeting closes on 30 Oct 2026
- Brokers: May cast discretionary votes on the proposal
- Reporting: Results will be filed in a Form 8‑K after the adjourned meeting
- Proxy card: No new card issued; the original remains valid
- Abstentions/unvoted shares: Do not affect the outcome of the reverse‑split vote
Related Stock Activity (Last 24 Hours)
| Symbol | Company | 24‑hour change | Current price | Market cap |
|---|---|---|---|---|
| YHC | Lqr House | ‑10.1 % | USD 1.78 | USD 2.6 million |
| VIVS | Vivosim Labs | +6.25 % | USD 0.17 | USD 2.6 million |
| ADGM | Adagio Medical | +0.83 % | USD 0.12 | USD 2.7 million |
| VVOS | Vivos Therapeutics | +4.44 % | USD 0.14 | USD 2.7 million |
Vivos Therapeutics Partnership Update
Vivos Therapeutics (VVOS) announced a strategic partnership with SOD Sciences. Key terms include:
- Acquisition of 11 % equity in SOD and 50 % co‑ownership of a pseudohypoxia early‑warning test
- Issuance of 12,000 shares of Series C Convertible Preferred Stock; no cash exchanged
- Joint marketing arrangement for Vivos’ sleep‑apnea treatments and SOD’s ReBalU Protocol, plus the shared test
- Equal sharing of revenue and costs related to the test’s intellectual property
- Expected expansion of Vivos’ access to sleep centres, clinics, and assisted‑living facilities, potentially creating new revenue streams
Company Overview
iSpecimen Inc. is a technology‑driven enterprise operating an online marketplace that connects researchers with specimen contributors. The platform streamlines specimen procurement and management, supporting global medical research initiatives.
